Main navigation

Fidelity Makes Major Push to Launch Bitcoin ETF

Advertisement
Wed, 15/09/2021 - 5:40
Fidelity Makes Major Push to Launch Bitcoin ETF
Cover image via stock.adobe.com
Read U.TODAY on
Google News

Mutual fund giant Fidelity had a WebEx meeting with the U.S. Securities and Exchange Commission on Sept. 8 to push for approval of its Bitcoin exchange-traded fund, according to a recent filing.  

Apart from Fidelity’s executives, the list of attendees included Kyle Murray, the vice president of Chicago-based futures exchange CBOE.

In the presentation, they put forward a variety of reasons as to why the product has to be approved by regulators.

They point to that the fact that the Bitcoin market has matured, touting its significant trading volume and its deep liquidity.   

Article image
Image by sec.gov

They also mention that both Canadian and European exchange-traded funds and exchange-traded products.

Fidelity says that investors will benefit from the ability to have direct exposure to Bitcoin through ETPs.

While some analysts believe that the SEC might be more inclined to initially approve a futures-based ETF, the presentation says that it doesn’t necessarily have to be an interim step.

The mutual fund giant also highlighted its long-time commitment to Bitcoin. Fidelity started exploring the largest cryptocurrency all the way back in 2014, significantly outpacing other Wall Street giants.

In March, FD Funds Management, a subsidiary of the Boston-based company, filed to launch a Bitcoin ETF called the Wise Origin Bitcoin Trust.

Related

As reported by U.Today, SEC Chair Gary Gensler said that he was looking forward to his commission reviewing a bunch of pending filings:    

Advertisement

I'm looking forward to what staff says about these filings.          

Related articles

Advertisement
TopCryptoNewsinYourMailbox
TopCryptoNewsinYourMailbox
Advertisement
Advertisement

Recommended articles

Latest Press Releases

Our social media
There's a lot to see there, too

Popular articles

Advertisement
AD